FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046090717> ?p ?o ?g. }

• W3046090717 endingPage "6311" @default.
• W3046090717 startingPage "6304" @default.
• W3046090717 abstract "Using laser capture microdissection (LCM) and sensitive human papillomavirus (HPV) genotyping, we aimed to determine the distribution of vaccine-preventable types in cervical intraepithelial neoplasia grade 3 (CIN3) lesions and adenocarcinoma in situ (AIS) in young women in Victoria, Australia, offered catch-up HPV vaccination, as a baseline for ongoing vaccine impact monitoring. We also compared findings with available pre-vaccination estimates from women with HPV detected on concurrently-collected cytology samples. Consecutive histologically-confirmed CIN3/AIS biopsies were collected between May 2011 and December 2014 from vaccine-eligible women (born after 30th June 1981). Genotypes present in whole tissue sections (WTS) were determined by a sensitive reverse hybridisation assay; RHA kit HPV SPF10-LiPA25, v1 (Labo Bio-medical Products). Where multiple genotypes were detected, lesions were isolated using LCM and genotyped. Cervical cytology samples from a pre-vaccine cohort had been previously collected and genotyped using HPV Linear Array HPV Genotyping Test (Roche Diagnostics). Mixed-genotype detections in this cohort were resolved to single-lesion-attributable genotypes using hierarchical attribution. Overall, 213 and 530 cases were included from pre- and post-vaccine time-periods, respectively. In 18–25 year-olds, the proportion of HPV16/18-positive CIN3/AIS decreased significantly over time from 69% in 2001–2005 (pre-vaccine), to 62% in 2011–2012 (post-vaccine), to 47% in 2013–2014 (p-trend = 0.004). There was no significant change in HPV16/18 in 26–32 year-olds (p-trend = 0.15). In 2013/14, nonavalent vaccine types accounted for 80% of CIN3/AIS in 18–25 year old women and 90% in 26–32 year old women. Four to 8 years following implementation of HPV vaccination in Australia, approximately 70% of CIN3/AIS in young women was due to HPV16/18. Our data, despite some limitations due to change in methods between pre- and post-vaccine periods, suggests that for vaccine-eligible women aged 18–25 at the time of biopsy, the proportion of HPV16/18-attributable CIN3/AIS lesions is significantly declining post-vaccination." @default.
• W3046090717 created "2020-08-03" @default.
• W3046090717 creator A5009474529 @default.
• W3046090717 creator A5014891010 @default.
• W3046090717 creator A5024203958 @default.
• W3046090717 creator A5046355615 @default.
• W3046090717 creator A5047316592 @default.
• W3046090717 creator A5053385424 @default.
• W3046090717 creator A5053554887 @default.
• W3046090717 creator A5056904986 @default.
• W3046090717 creator A5078117828 @default.
• W3046090717 creator A5091433029 @default.
• W3046090717 date "2020-09-01" @default.
• W3046090717 modified "2023-10-18" @default.
• W3046090717 title "HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination" @default.
• W3046090717 cites W1588414837 @default.
• W3046090717 cites W1893383646 @default.
• W3046090717 cites W1967809962 @default.
• W3046090717 cites W1976576506 @default.
• W3046090717 cites W1991635106 @default.
• W3046090717 cites W2002721615 @default.
• W3046090717 cites W2008958654 @default.
• W3046090717 cites W2017107670 @default.
• W3046090717 cites W2022709369 @default.
• W3046090717 cites W2031783384 @default.
• W3046090717 cites W2034471415 @default.
• W3046090717 cites W2038748174 @default.
• W3046090717 cites W2041694981 @default.
• W3046090717 cites W2043746949 @default.
• W3046090717 cites W2051034663 @default.
• W3046090717 cites W2058399080 @default.
• W3046090717 cites W2068551630 @default.
• W3046090717 cites W2116827928 @default.
• W3046090717 cites W2118213020 @default.
• W3046090717 cites W2125054141 @default.
• W3046090717 cites W2127043059 @default.
• W3046090717 cites W2127728552 @default.
• W3046090717 cites W2129827681 @default.
• W3046090717 cites W2130167819 @default.
• W3046090717 cites W2131103881 @default.
• W3046090717 cites W2146728505 @default.
• W3046090717 cites W2153692195 @default.
• W3046090717 cites W2155071719 @default.
• W3046090717 cites W2160354963 @default.
• W3046090717 cites W2165722018 @default.
• W3046090717 cites W2169182621 @default.
• W3046090717 cites W2171662239 @default.
• W3046090717 cites W2314590113 @default.
• W3046090717 cites W2800236160 @default.
• W3046090717 cites W2886883561 @default.
• W3046090717 cites W2917436894 @default.
• W3046090717 cites W2939003533 @default.
• W3046090717 cites W2955245499 @default.
• W3046090717 doi "https://doi.org/10.1016/j.vaccine.2020.07.037" @default.
• W3046090717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32736938" @default.
• W3046090717 hasPublicationYear "2020" @default.
• W3046090717 type Work @default.
• W3046090717 sameAs 3046090717 @default.
• W3046090717 citedByCount "7" @default.
• W3046090717 countsByYear W30460907172021 @default.
• W3046090717 countsByYear W30460907172022 @default.
• W3046090717 crossrefType "journal-article" @default.
• W3046090717 hasAuthorship W3046090717A5009474529 @default.
• W3046090717 hasAuthorship W3046090717A5014891010 @default.
• W3046090717 hasAuthorship W3046090717A5024203958 @default.
• W3046090717 hasAuthorship W3046090717A5046355615 @default.
• W3046090717 hasAuthorship W3046090717A5047316592 @default.
• W3046090717 hasAuthorship W3046090717A5053385424 @default.
• W3046090717 hasAuthorship W3046090717A5053554887 @default.
• W3046090717 hasAuthorship W3046090717A5056904986 @default.
• W3046090717 hasAuthorship W3046090717A5078117828 @default.
• W3046090717 hasAuthorship W3046090717A5091433029 @default.
• W3046090717 hasConcept C104317684 @default.
• W3046090717 hasConcept C121608353 @default.
• W3046090717 hasConcept C126322002 @default.
• W3046090717 hasConcept C135763542 @default.
• W3046090717 hasConcept C142724271 @default.
• W3046090717 hasConcept C159047783 @default.
• W3046090717 hasConcept C18823058 @default.
• W3046090717 hasConcept C22070199 @default.
• W3046090717 hasConcept C2777343196 @default.
• W3046090717 hasConcept C2778220009 @default.
• W3046090717 hasConcept C2778580637 @default.
• W3046090717 hasConcept C2780647465 @default.
• W3046090717 hasConcept C2908647359 @default.
• W3046090717 hasConcept C29456083 @default.
• W3046090717 hasConcept C31467283 @default.
• W3046090717 hasConcept C55493867 @default.
• W3046090717 hasConcept C71924100 @default.
• W3046090717 hasConcept C72563966 @default.
• W3046090717 hasConcept C86803240 @default.
• W3046090717 hasConcept C99454951 @default.
• W3046090717 hasConceptScore W3046090717C104317684 @default.
• W3046090717 hasConceptScore W3046090717C121608353 @default.
• W3046090717 hasConceptScore W3046090717C126322002 @default.
• W3046090717 hasConceptScore W3046090717C135763542 @default.
• W3046090717 hasConceptScore W3046090717C142724271 @default.
• W3046090717 hasConceptScore W3046090717C159047783 @default.

• next